Last reviewed · How we verify
LY3650150
LY3650150 is a GLP-1 receptor agonist that activates the glucagon-like peptide-1 receptor to improve glycemic control and promote weight loss.
LY3650150 is a GLP-1 receptor agonist that activates the glucagon-like peptide-1 receptor to improve glycemic control and promote weight loss. Used for Type 2 diabetes mellitus, Obesity or weight management.
At a glance
| Generic name | LY3650150 |
|---|---|
| Sponsor | Eli Lilly and Company |
| Drug class | GLP-1 receptor agonist |
| Target | GLP-1R |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
GLP-1 receptor agonists enhance insulin secretion in response to glucose, slow gastric emptying, and promote satiety through central nervous system effects. LY3650150 is being developed as a next-generation GLP-1 agonist with potential for improved efficacy or dosing convenience compared to existing agents in this class.
Approved indications
- Type 2 diabetes mellitus
- Obesity or weight management
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Abdominal pain
Key clinical trials
- A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1) (PHASE3)
- A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP) (PHASE3)
- A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden (PHASE4)
- A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color (PHASE3)
- A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis (PHASE3)
- A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab (PHASE3)
- A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis (PHASE3)
- A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |